Kenneth Ain, MD
Endocrinology, Diabetes & Metabolism · Lexington, KYNPI 1396857173
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Exelixis Inc. accounts for 75.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $1,980 and has fallen 89.9% since, to $200 in 2024.
Across 16 payments — averaging $312.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$4K
- Bayer$880
- Sanofi$325
Across 54 payments — averaging $2973.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$102K
- Shire North American Group Inc$24K
- Chugai Pharmaceutical Co., Ltd.$21K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
What the payments were for
- Consulting fees$88018%
- Speaking & faculty fees$2,30546%
- Travel & lodging$1,35927%
- Food & beverage$4589%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 13 | $3,797 |
| Bayer | 1 | $880 |
| Sanofi | 2 | $325 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,002 in reported general payments places this provider in the 60th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 24 | $499,169 |
| RetevmoSelpercatinib | 22 | $488,803 |
| SorafenibSorafenib Tosylate | 43 | $468,250 |
| MekinistTrametinib Dimethyl Sulfoxide | 26 | $425,203 |
| TafinlarDabrafenib Mesylate | 23 | $324,180 |
| Levothyroxine Sodium | 519 | $7,659 |
| SynthroidLevothyroxine Sodium | 18 | $1,739 |
| Calcitriol | 80 | $1,667 |
| Labetalol Hcl | 29 | $1,192 |
| Metoprolol Succinate | 74 | $985 |
| Losartan Potassium | 64 | $652 |
| Prazosin Hcl | 13 | $600 |
| Amlodipine Besylate | 102 | $498 |
| Lisinopril | 64 | $478 |
| Atenolol | 20 | $89 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Lexington
- Lyle MyersLexington$60K
- Wendell MiersLexington$38K
- Leera PatelLexington$34K
- Simon FisherLexington$26K
- Anna MarinoLexington$23K
- Gordon GuthrieLexington$14K
- Megan MinchLexington$4K
- Walaa AyoubLexington$3K
- Kristina HumphriesLexington$3K
- Dennis KarounosLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.